Patients with a history of hepatic sinusoid obstructive syndrome (veno-occlusive disease) within the prior 3 monthsXx_NEWLINE_xXKnown history of Gilbert's syndromeXx_NEWLINE_xXPresence of GVHD overlap syndrome.Xx_NEWLINE_xXMyelodysplastic syndrome with isolated del(5q) (5q-syndrome)Xx_NEWLINE_xXMyelodysplastic syndrome (MDS), unclassifiableXx_NEWLINE_xXAbnormal glucuronidation of bilirubin, known Gilbert's syndromeXx_NEWLINE_xXHistory of reversible posterior leukoencephalopathy syndrome (RPLS)Xx_NEWLINE_xXTrisomy 21 (Down syndrome)Xx_NEWLINE_xXPatients known to have one of the following concomitant genetic syndromes: Down syndrome, Bloom syndrome, ataxia-telangiectasia, Fanconi anemia, Kostmann syndrome, Shwachman syndrome or any other known bone marrow failure syndromeXx_NEWLINE_xXPatients with Down syndromeXx_NEWLINE_xXPatients with Down syndrome are not eligibleXx_NEWLINE_xXDown syndromeXx_NEWLINE_xXPatients with congenital long QT syndrome, history of ventricular arrhythmias or heart blockXx_NEWLINE_xXPatients with down syndrome are excluded from this studyXx_NEWLINE_xXPatients with known symptomatic Fanconi anemia (FA), ataxia-telangiectasia (A-T) syndrome, Bloom syndrome (BS) and Nijmegen breakage syndrome (NBS) are not eligible (asymptomatic carriers are acceptable)Xx_NEWLINE_xXHistory of sarcoidosis syndromeXx_NEWLINE_xXDifficulty with swallowing or an active malabsorption syndrome.Xx_NEWLINE_xXPatients must not have evidence or history of veno-occlusive disease or sinusoidal obstruction syndromeXx_NEWLINE_xXHistory of known radiation sensitivity syndromeXx_NEWLINE_xXPatients with congenital long QT syndromeXx_NEWLINE_xXPOEMS syndromeXx_NEWLINE_xXRelapsed or refractory myelodysplastic syndrome (MDS), International Prognostic Scoring System intermediate or high-risk, with no available therapiesXx_NEWLINE_xXSubjects with Gilbert's syndrome;Xx_NEWLINE_xXMyelodysplastic or myeloproliferative syndrome other than MDS.Xx_NEWLINE_xXAcute coronary syndrome within 6 months prior to starting treatmentXx_NEWLINE_xXParticipants with Gilbert's syndrome will be eligible for the studyXx_NEWLINE_xXQTc >480 msec, or family or personal history of long or short QT syndrome, Brugada syndrome or known history of QTc prolongation, or Torsade de Pointes.Xx_NEWLINE_xXMycosis fungoide/Sezary syndromeXx_NEWLINE_xXHistory of Steven's Johnson's syndrome or toxic epidermal necrolysis syndrome.Xx_NEWLINE_xXHistory of nephrotic syndromeXx_NEWLINE_xXUncorrectable electrolyte abnormalities, long QT syndrome or taking medications known to prolong the QT intervalXx_NEWLINE_xXPatients with nevoid BCC syndrome (Gorlin syndrome) should not enroll in this studyXx_NEWLINE_xXAcute coronary syndromeXx_NEWLINE_xXMyelodysplastic Syndrome (MDS)Xx_NEWLINE_xXParticipants with a personal or family history of long QT syndromeXx_NEWLINE_xXHave a history of Gilbert's syndrome.Xx_NEWLINE_xXPre-existing renal disease including glomerulonephritis, nephritic syndrome, Fanconi Syndrome or renal tubular acidosis.Xx_NEWLINE_xXAny history of serotonin syndrome (SS) after receiving 1 or more serotonergic drugsXx_NEWLINE_xXCongenital long QT syndromeXx_NEWLINE_xXKnown history of Gilbert's syndrome.Xx_NEWLINE_xXMyelodysplastic syndromeXx_NEWLINE_xXPatients with Down’s syndromeXx_NEWLINE_xXENROLLMENT TO THE DOSE ESCALATION, EXPANSION AND PART II: History of QT syndrome, Brugada syndrome, known history of QTc prolongation, or Torsades de PointesXx_NEWLINE_xXENROLLMENT TO THE DOSE ESCALATION, EXPANSION AND PART II: History of Gilbert’s syndromeXx_NEWLINE_xXEXPANDED ACCESS COHORT: History of QT syndrome, Brugada syndrome, known history of clinically significant QTc prolongation, or Torsades de PointesXx_NEWLINE_xXAML that progressed out of myelodysplastic syndrome (MDS) is eligible if the patient did not receive treatment directed at the MDSXx_NEWLINE_xXParticipants with a personal or family history of long QT syndromeXx_NEWLINE_xXPatients with Down syndromeXx_NEWLINE_xXNo known history of prolonged QT syndromeXx_NEWLINE_xXHistory of hemolytic-uremic syndrome.Xx_NEWLINE_xXParticipant has long QT Syndrome at screening.Xx_NEWLINE_xXAny factors that increase the risk of QTc prolongation or risk of arrhythmic events such as heart failure, hypokalemia, congenital long QT syndrome, family history of long QT syndrome or unexplained sudden death under 40 years of age in first degree relatives or any concomitant medication known to prolong the QT interval.Xx_NEWLINE_xXKnown history of Gilbert's Syndrome.Xx_NEWLINE_xXParticipants with a personal or family history of long QT syndrome.Xx_NEWLINE_xXMyeloproliferative/myelodysplastic syndrome other than CMML. CMML with t(5;12) that have not yet received imatinib.Xx_NEWLINE_xXAny factors that increase the risk of QTc prolongation or risk of rrhythmic events such as heart failure, hypokalemia, congenital long QT syndrome, family history of long QT syndrome or unexplained sudden death under 40 years-of-age, or any concomitant medication known to prolong the QT intervalXx_NEWLINE_xXBilirubin =< 3.0 mg/dL (unless due to Gilbert’s syndrome or hemolysis) for patients receiving MAC, RIC or RIC-MMF and bilirubin =< 5.0 mg/dL for patients receiving IOC (unless due to Gilbert’s syndrome or hemolysis)Xx_NEWLINE_xXHistory of congenital long QT syndrome or torsades de pointesXx_NEWLINE_xXAny evidence of myelodysplastic syndrome or marrow chromosomal changes suggesting myelodysplasia (-7, -5 etc)Xx_NEWLINE_xXHistory of sarcoidosis syndromeXx_NEWLINE_xXPatients with a prior history of drug-induced serotonin syndrome, or a family history of long-QT syndromeXx_NEWLINE_xXPatients with congenital long QT syndrome (for cohort 2a and 2b [belinostat cohorts] only, electrocardiogram [ECG] not required for cohort 1)Xx_NEWLINE_xXHistory of known malabsorption syndrome or prior surgery(ies) that may lead to malabsorptionXx_NEWLINE_xXCongenital long QT syndromeXx_NEWLINE_xXNo congenital long QT syndrome or known 1st degree relative with unexplained sudden death under 40 years of ageXx_NEWLINE_xXHistory of multiple sclerosis or other demyelinating disease and/or Eaton-Lambert syndrome (para-neoplastic syndrome)Xx_NEWLINE_xXCurrent or history of ventricular or life-threatening arrhythmias or diagnosis of long-QT syndromeXx_NEWLINE_xXBilirubin ? 3.0 x ULN, unless due to Gilbert’s syndrome (unless considered due to leukemic organ involvement)Xx_NEWLINE_xXSubject has received treatment with a hypomethylating agent and/or other chemotherapeutic agent either conventional or experimental for myelodysplastic syndrome (MDS) or AMLXx_NEWLINE_xXAny history of serotonin syndrome after receiving serotonergic drugsXx_NEWLINE_xXDocumented history of carcinoid syndromeXx_NEWLINE_xXPatients with Gilbert's syndrome will be eligible for the study; the diagnosis of Gilbert's syndrome is suspected in people who have persistent, slightly elevated levels of unconjugated bilirubin without any other apparent cause; a diagnosis of Gilbert's syndrome will be based on the exclusion of other diseases based on the following criteria:\r\n* Unconjugated hyperbilirubinemia noted on several occasions\r\n* No evidence of hemolysis (normal hemoglobin, reticulocyte count, and lactate dehydrogenase [LDH])\r\n* Normal liver function tests\r\n* Absence of other diseases associated with unconjugated hyperbilirubinemiaXx_NEWLINE_xXAny factors that increase the risk of QTc prolongation or risk of arrhythmic events such as heart failure, hypokalaemia, congenital long QT syndrome, family history of long QT syndrome or unexplained sudden death under 40 years-of-age, or any concomitant medication known to prolong the QT intervalXx_NEWLINE_xXSubjects with history of or active symptoms of carcinoid syndromeXx_NEWLINE_xXAny history of serotonin syndrome (SS) after receiving serotonergic drugsXx_NEWLINE_xXPresence of risk factors for torsade de pointes, including family history of Long QT Syndrome or uncorrected hypokalemia.Xx_NEWLINE_xXKnown reversible posterior leukoencephalopathy syndrome (RPLS)Xx_NEWLINE_xXHistory of concomitant genetic syndrome such as Fanconi anemia, Kostmann syndrome, Shwachman-Diamond syndrome or any other known bone marrow failure syndromeXx_NEWLINE_xXHistory of multiple sclerosis or other demyelinating disease, Eaton-Lambert syndrome (para-neoplastic syndrome), history of hemorrhagic or ischemic stroke within the last 6 months, or alcoholic liver disease;Xx_NEWLINE_xXA hypomethylating agent, venetoclax and/or chemo therapeutic agent for Myelodysplastic syndrome (MDS).Xx_NEWLINE_xXHistory of Gilbert’s syndromeXx_NEWLINE_xXAny history of serotonin syndrome (SS) after receiving serotonergic drugsXx_NEWLINE_xXFamily or personal history of long QT syndromeXx_NEWLINE_xXHas any factors that increase the risk of QTc prolongation or risk of arrhythmic events, such as congenital long QT. syndrome, family history of long QT syndrome or unexplained sudden death under 40 years of age in first degree relatives.Xx_NEWLINE_xXDocumented history of capillary leak syndrome within 6 months of study enrollment.Xx_NEWLINE_xXHistory of sarcoidosis syndromeXx_NEWLINE_xXPatients with congestive heart failure, congenital long QT syndrome; bradyarrhythmias, drugs known to prolong the QT intervalXx_NEWLINE_xXAbsence of history of congenital long QT syndromeXx_NEWLINE_xXPatients with respiratory distress syndromeXx_NEWLINE_xXHas any history of serotonin syndrome after receiving 1 or more serotonergic drugsXx_NEWLINE_xXFamily history of long QTc syndrome; personal history of long QTc syndrome or previous drug-induced QTc prolongation of at least Grade 3 (QTc >500 ms).Xx_NEWLINE_xXAny other significant medical condition not under control, including any acute coronary syndrome within the past 6 monthsXx_NEWLINE_xXHas history of reversible posterior leukoencephalopathy syndromeXx_NEWLINE_xXHistologic diagnosis of Richter’s syndrome (RS)Xx_NEWLINE_xXHistory of sarcoidosis syndromeXx_NEWLINE_xXTotal bilirubin =< 1.5 X upper limit of normal (ULN), for patients with congenital unconjugated hyperbilirubinemia (Crigler-Najjar syndrome type 1 and 2, Gilbert syndrome) that transient hyperbilirubinemia can occur due to physiological condition, as long as there is clear documentation of diagnosis, allowed to be enrolled if direct (conjugated) bilirubin is 1.5 X ULNXx_NEWLINE_xXHistory of risk factors for TdP, including family history of long QT syndrome.Xx_NEWLINE_xXLong QT syndrome or family history of idiopathic sudden death or congenital long QT syndrome.Xx_NEWLINE_xXCongenital long QT syndrome or family history of unexpected sudden cardiac deathXx_NEWLINE_xXAny factors that increase the risk of QTc prolongation or risk of arrhythmic events such as heart failure, hypokalaemia, congenital long QT syndrome, immediate family history of long QT syndrome or unexplained sudden death under 40 years of ageXx_NEWLINE_xXAny history of congenital long QT syndromeXx_NEWLINE_xXKnown congenital long QT syndromeXx_NEWLINE_xXHistory of congenital long QT syndrome or torsades de pointesXx_NEWLINE_xXCongenital long QT syndromeXx_NEWLINE_xXHistory of risk factors for torsades de pointes (e.g., heart failure, hypokalemia, family history of long QT syndrome); concomitant use of medications with a low risk of QT/QTc prolongation (including, but not limited to diphenhydramine, famotidine, ondansetron) is permissibleXx_NEWLINE_xXPatients with Gilbert's syndrome or other heritable diseases of bile processing.Xx_NEWLINE_xXAny factors that increase the risk of QTc prolongation or risk of arrhythmic events such as heart failure, hypokalaemia, congenital long QT syndrome, family history of long QT syndrome or unexplained sudden death under 40 years-of-age, or any concomitant medication known to prolong the QT intervalXx_NEWLINE_xXHas a paraneoplastic syndrome other than syndrome of inappropriate antidiuretic hormone secretion (SIADH) (hyponatremia)Xx_NEWLINE_xXKnown family or personal history of long corrected QT (QTc) syndrome or ventricular arrhythmias including ventricular bigeminyXx_NEWLINE_xXPOEMS syndrome requiring therapy, previously treated or untreatedXx_NEWLINE_xXHistory of serious ventricular arrhythmia (VT or VF, ? 3 beats in a row) and/or risk factors (e.g., heart failure, hypokalemia, family history of Long QT Syndrome)Xx_NEWLINE_xXMyelodysplastic syndrome, myeloproliferative neoplasms, or myelodysplastic syndrome/myeloproliferative neoplasms (MDS/MPN) overlap syndrome with:\r\n* International prognostic scoring system risk score of intermediate (INT)-2 or high risk at the time of transplant evaluation\r\n* Any risk category if life-threatening cytopenia exists\r\n* Karyotype or genomic changes that indicate high risk for progression to acute myelogenous leukemia, including abnormalities of chromosome 7 or 3, mutations of TP53, or complex or monosomal karyotypeXx_NEWLINE_xXHistory or family history of long QT syndrome.Xx_NEWLINE_xXDemyelinating form of Charcot-Marie-Tooth syndromeXx_NEWLINE_xXKnown Gilbert’s syndromeXx_NEWLINE_xXHistory of sarcoidosis syndromeXx_NEWLINE_xXUntreated secondary AML, including AML that has progressed from myelodysplastic syndrome (MDS)Xx_NEWLINE_xXDiagnosed congenital long QT syndromeXx_NEWLINE_xXClinically significant electrocardiogram (ECG) changes at enrollment which obscure the ability to assess the PR, QT, and QRS interval; congenital long QT syndrome.Xx_NEWLINE_xXPatients with known Gilbert syndrome are not eligibleXx_NEWLINE_xXHistory of congenital long QT syndromeXx_NEWLINE_xXhistory of erythema multiforme, toxic epidermal necrolysis or Stevens-Johnson syndrome;Xx_NEWLINE_xXHistory of congenital long QT syndromeXx_NEWLINE_xXHistory of serious ventricular arrhythmia (VT or VF, ? 3 beats in a row) and/or risk factors (e.g., heart failure, hypokalemia, family history of Long QT Syndrome)Xx_NEWLINE_xXPatients with known Gilbert's syndrome or reduced UGT1A1 activity.Xx_NEWLINE_xXPersonal history of Gilbert’s syndromeXx_NEWLINE_xXPHASE II: Resting ECG with QTc > 470msec on two or more time points within a 24h period, or a family history of long QT syndromeXx_NEWLINE_xXDown syndromeXx_NEWLINE_xXDirect bilirubin must be < 2 mg/dL unless the elevation is known to be due to Gilbert's syndrome or acute GVHD (aGVHD) within 3 days of enrollmentXx_NEWLINE_xXPatients with chronic GVHD only; patients diagnosed with overlap syndrome are still eligibleXx_NEWLINE_xXIndividuals with Down syndromeXx_NEWLINE_xXCongenital long QT syndromeXx_NEWLINE_xXHistory of serotonergic syndromeXx_NEWLINE_xXMyelodysplastic syndrome\r\n* Refractory anemia with excess blasts (RAEB) I or II\r\n* High-risk International Prognostic Scoring System (IPSS)\r\n* Secondary myelodysplastic syndrome (MDS)Xx_NEWLINE_xXAny history of Stevens-Johnson syndromeXx_NEWLINE_xXPatients with an inherited cancer syndrome or a medical history suggestive of an inherited cancer syndrome remain eligibleXx_NEWLINE_xXNo prior history of myelodysplastic syndrome or other myeloid malignancyXx_NEWLINE_xXPatients with known Gilbert’s syndromeXx_NEWLINE_xXSubjects with Gorlin syndromeXx_NEWLINE_xXPrior treatment of myelodysplastic syndrome or myeloproliferative neoplasm with hypomethylating agent acceptableXx_NEWLINE_xXBilirubin equal or less than 1.5 (unless Gilbert's syndrome)Xx_NEWLINE_xXPatients with concomitant genetic syndrome: patients with Down syndrome, Fanconi anemia, Kostmann syndrome, Shwachman syndrome or any other known bone marrow failure syndromeXx_NEWLINE_xXHistory of Gilbert's syndromeXx_NEWLINE_xXMalabsorption syndrome, such as Crohn’s diseaseXx_NEWLINE_xXA history of additional risk factors for torsades de pointes (e.g., heart failure, hypokalemia, family history of long QT syndrome, etc.)Xx_NEWLINE_xXNo history of Steven’s Johnson’s syndrome, toxic epidermal necrolysis (TEN)s syndrome, or motor neuropathyXx_NEWLINE_xXRANDOMIZED PHASE II (ARMS K AND L): No history of Steven’s Johnson’s syndrome, TENs syndrome, or motor neuropathyXx_NEWLINE_xXKnown family history of congenital long QT syndrome.Xx_NEWLINE_xXPatients with congenital long QT syndromeXx_NEWLINE_xXHistory of Gilbert’s syndromeXx_NEWLINE_xXPatients with a diagnosis of myelodysplastic syndrome/myeloproliferative neoplasm, unclassifiable (MDS/MPN-U) that require therapyXx_NEWLINE_xXAcute IA defined as duration of clinical syndrome of <30 days.Xx_NEWLINE_xXA history of additional risk factors for torsade de pointes (e.g., heart failure, hypokalemia, family history of long QT syndrome)Xx_NEWLINE_xXPHASE II: Diagnosis of AML in remission 1 or 2 or a diagnosis of myelodysplastic syndrome either intermediate 1 or 2, or high risk by the International Prognostic Scoring SystemXx_NEWLINE_xXDiagnosed congenital long QT syndromeXx_NEWLINE_xXCongenital long QT syndromeXx_NEWLINE_xXMyelodysplastic syndrome with multi-lineage dysplasia with or without chromosomal abnormalitiesXx_NEWLINE_xXMyelodysplastic syndromeXx_NEWLINE_xXHistory of multiple sclerosis or other demyelinating disease, Eaton-Lambert syndrome (para-neoplastic syndrome), history of hemorrhagic or ischemic stroke within the last 6 months, or alcoholic liver disease;Xx_NEWLINE_xXSubject has gastric outlet syndrome or persistent/recurrent vomiting.Xx_NEWLINE_xXAny factor increasing the risk of QTc prolongation or risk of arrhythmic events such as heart failure, hypokalemia, congenital long QT syndrome, family history of long QT syndrome, or unexplained sudden death under 40 years of age in first-degree relatives, or any concomitant medication known to prolong the QT interval.Xx_NEWLINE_xXKnown history of myelodysplastic syndrome/leukemia at any timeXx_NEWLINE_xXCurrent alcohol abuse syndromeXx_NEWLINE_xXActive alcohol abuse syndromeXx_NEWLINE_xXCriteria 5 Myelodysplastic syndromeXx_NEWLINE_xXKnown presence of intermediate- or high-grade myelodysplastic syndrome.Xx_NEWLINE_xXKnown history of serious allergic reaction including anaphylaxis or Stevens- Johnson syndrome/ toxic epidermal necrolysisXx_NEWLINE_xXMust not have a family history of long QTc syndromeXx_NEWLINE_xXMyelodysplastic syndrome (MDS) or myelofibrosis;Xx_NEWLINE_xXPOEMS syndromeXx_NEWLINE_xXMyelodysplastic syndrome (MDS): primary or therapy relatedXx_NEWLINE_xXDifficulty with swallowing, or an active malabsorption syndrome.Xx_NEWLINE_xXDifficulty with swallowing or an active malabsorption syndromeXx_NEWLINE_xXPatients with HNPCC (Lynch Syndrome)Xx_NEWLINE_xXDiagnosis of myelodysplastic syndrome.Xx_NEWLINE_xXHistory of lymphoma (Richter’s syndrome) unless in complete remission > 2 years without\r\nrelapseXx_NEWLINE_xXA history of additional risk factors for Torsade de Pointes (e.g., clinically significant heart failure, hypokalemia, family history of long QT syndrome)Xx_NEWLINE_xXHistory of Gilbert syndromeXx_NEWLINE_xXHistory of long-QT syndromeXx_NEWLINE_xXHas any history of serotonin syndrome after receiving serotonergic drugsXx_NEWLINE_xXHistory of congenital long QT syndrome or torsades de pointesXx_NEWLINE_xXDown syndromeXx_NEWLINE_xXKostmann syndromeXx_NEWLINE_xXShwachman syndromeXx_NEWLINE_xXNo known Gilbert’s syndrome or known homozygosity for UGAT1A1*28 polymorphismXx_NEWLINE_xXHistory of Gilbert's syndromeXx_NEWLINE_xXHave received a hypomethylating agent for myelodysplastic syndrome (MDS).Xx_NEWLINE_xXPatient has a history of Stevens-Johnson-Syndrome (SJS) or Toxic Epidermal Necroloysis (TEN)Xx_NEWLINE_xXSubject has Acute Respiratory Distress Syndrome (ARDS)Xx_NEWLINE_xXPatients known to have one of the following concomitant genetic syndromes: Bloom syndrome, ataxia-telangiectasia, Fanconi anemia, Kostmann syndrome, Shwachman syndrome, or any other known bone marrow failure syndromeXx_NEWLINE_xXDocumented Gilbert’s syndromeXx_NEWLINE_xXA history of additional risk factors for torsade de pointes (e.g., heart failure, hypokalemia, family history of Long QT Syndrome).Xx_NEWLINE_xXDiagnosis of Down syndrome (Trisomy 21)Xx_NEWLINE_xXHistory of Gilbert’s syndromeXx_NEWLINE_xXPatients with a history of myelodysplastic syndrome (MDS)Xx_NEWLINE_xXPatients with any of the following diagnoses:\r\n* Acute promyelocytic leukemia (APL)\r\n* Down syndrome\r\n* Fanconi anemia, Kostmann syndrome, Shwachman syndrome or any other known bone marrow failure syndrome\r\n* Wilson's disease and any other disorder of copper metabolism\r\n* Juvenile myelomonocytic leukemia (JMML)Xx_NEWLINE_xXPatients with Li Fraumeni syndrome are excluded from the studyXx_NEWLINE_xXRadiosensitivity syndrome (scleroderma, dermatomyositis, other genetic syndrome that predisposes to adverse radiotherapy complications)Xx_NEWLINE_xXCongenital long QT syndrome or history of torsades de pointesXx_NEWLINE_xXPatients with a family history or Li-Fraumeni syndrome will not be eligibleXx_NEWLINE_xXPersonal or family history of long QT syndromeXx_NEWLINE_xXClinically significant cardiac arrhythmias, prolonged QT interval, congenital long QT syndromeXx_NEWLINE_xXHistory of posterior reversible encephalopathy syndromeXx_NEWLINE_xXPatients must not have a screening QTcF interval > 480 msec based on the average of the triplicate EKGs performed within 28 days prior to step 2 re-registration; NOTE: triplicate EKGs are required at other timepoints; patients must not have any family or personal history of long or short QT syndrome, Brugada syndrome or known history of QTc prolongation, or torsade de pointesXx_NEWLINE_xXPatients with Fanconi anemia, Kostmann syndrome, Shwachman syndrome, or other inherited bone marrow failure syndromes are not eligibleXx_NEWLINE_xXCongenital long QT syndromeXx_NEWLINE_xXPatients who have experienced bowel perforation, neurologic involvement, Guillain Barré syndrome, Myasthenia Gravis, Steven Johnson syndrome and other intractable events or grade 4 non-laboratory toxicityXx_NEWLINE_xXA history of additional risk factors for torsade de pointes (e.g., clinically significant heart failure, hypokalemia, family history of long QT syndrome)Xx_NEWLINE_xXPatients with congenital long QT syndrome are excludedXx_NEWLINE_xXPatients with a history of toxic epidermal necrolysis (TEN) or Stevens-Johnson syndrome are excludedXx_NEWLINE_xXPre-existing nephritic syndromeXx_NEWLINE_xXSubjects with Long QT Syndrome at Screening.Xx_NEWLINE_xXHistory of another primary invasive cancer, hematologic malignancy, or myelodysplastic syndrome that has not been in remission for at least 1 yearXx_NEWLINE_xXSubject has Down syndrome.Xx_NEWLINE_xXPresence of GVHD overlap syndrome as per NIH guidelines.Xx_NEWLINE_xXFor Cohort A: Has myelodysplastic syndromeXx_NEWLINE_xXPatients with concomitant genetic syndrome: such as patients with Fanconi anemia, Kostmann syndrome, Shwachman syndrome or any other known bone marrow failure syndrome. Patients with Down Syndrome will not be excluded.Xx_NEWLINE_xXAny clinically significant pre-existing severe renal disease (eg, glomerulonephritis, nephritic syndrome, Fanconi Syndrome or renal tubular acidosis) or high risk of developing severe renal impairment.Xx_NEWLINE_xXHistory of Stevens-Johnson syndrome or toxic epidermal necrolysis syndrome.Xx_NEWLINE_xXKnown prolymphocytic leukemia or history of, or currently suspected, Richter's syndrome.Xx_NEWLINE_xXKnown prolymphocytic leukemia or history of, or currently suspected, Richter's syndrome.Xx_NEWLINE_xXCongenital long QT syndrome or family history of long QT syndromeXx_NEWLINE_xXRichter syndromeXx_NEWLINE_xXPatients with peripheral arterial disease with intermittent claudication or Leriches SyndromeXx_NEWLINE_xXSubjects who have history of toxic epidermal necrolysis or Stevens-Johnson syndrome;Xx_NEWLINE_xXSubjects with hypothyroidism (eg, following Hashimoto syndrome) stable on hormone replacement; orXx_NEWLINE_xXHad prior serotonin syndromeXx_NEWLINE_xXPatients with concomitant genetic syndrome: such as patients with Fanconi anemia, Kostmann syndrome, Shwachman syndrome or any other known bone marrow failure syndrome. Patients with Down Syndrome will not be excluded.Xx_NEWLINE_xXHistory of additional risk factors for torsade de pointes (e.g., family history of long QT syndrome).Xx_NEWLINE_xXPresence of known intermediate- or high-grade myelodysplastic syndromeXx_NEWLINE_xXPatients must not have known Gilbert’s syndromeXx_NEWLINE_xXKnown history or presence of Sweet Syndrome at screeningXx_NEWLINE_xXHistory of Steven's Johnson's syndrome or toxic epidermal necrolysis syndrome.Xx_NEWLINE_xXHistory of posterior reversible encephalopathy syndrome.Xx_NEWLINE_xXKnown Gilbert's syndromeXx_NEWLINE_xXPatients considered at risk for life-threatening QTc prolongation (i.e., personal or family history of Long QT syndrome, presence of implantable pacemaker, or implantable cardioverter defibrillator, etc.)Xx_NEWLINE_xXNo history of erythema multiforme, toxic epidermal necrolysis or Stevens-Johnson syndromeXx_NEWLINE_xXHistory of long QT syndrome or a family member with this conditionXx_NEWLINE_xXPOEMS syndromeXx_NEWLINE_xXLong QT syndrome or family history of idiopathic sudden death or congenital long QT syndrome, and etc.Xx_NEWLINE_xXCurrent or history of ventricular or life-threatening arrhythmias or diagnosis of long-QT syndromeXx_NEWLINE_xXCongenital long QT syndrome.Xx_NEWLINE_xXAny history of serotonin syndrome after receiving serotonergic drugs.Xx_NEWLINE_xXLong QT SyndromeXx_NEWLINE_xXHistory of sarcoidosis syndromeXx_NEWLINE_xXHave ongoing or recent (?6 months) hepatorenal syndrome.Xx_NEWLINE_xXLong QT syndrome or family history of idiopathic sudden death or congenital long QT syndrome, or any of the following:Xx_NEWLINE_xXCongenital long QT syndrome or taking drugs known to prolong the QT intervalXx_NEWLINE_xXMyelodysplastic syndromeXx_NEWLINE_xXPatients who have a known inherited syndrome as the cause for hormone over secretion.Xx_NEWLINE_xXPatients must not have a known history of Gilbert’s syndrome or known homozygosity for the UDP glucuronosyltransferase 1 family, polypeptide A1 (UGT1A1)*28 alleleXx_NEWLINE_xXHistory of Osler-Weber-Rendu syndrome or hereditary hemorrhagic telangiectasiaXx_NEWLINE_xXKnown history of myelodysplastic syndrome (MDS).Xx_NEWLINE_xXDiagnosed or suspected congenital long QT syndromeXx_NEWLINE_xXPatients must not have been diagnosed with myelodysplastic syndrome or with any malignancy other than neuroblastomaXx_NEWLINE_xXKnown to have a hypercoagulability syndrome (e.g.: antithrombin III, deficiency, anticardiolipin syndrome etc)Xx_NEWLINE_xXSubject with a history of Long QT Syndrome at screening.Xx_NEWLINE_xXHistory of concomitant genetic syndrome such as Fanconi anemia, Kostmann syndrome, Shwachman-Diamond syndrome or any other known bone marrow failure syndromeXx_NEWLINE_xXSubjects with known Gilbert's syndrome who have serum bilirubin ? 3 x ULN (NCI CTCAE v4.03 Grade 2) may be enrolled.Xx_NEWLINE_xXPre-existing renal disease including glomerulonephritis, nephritic syndrome, Fanconi syndrome or renal tubular acidosisXx_NEWLINE_xXConcomitant medications known to prolong QT interval, or with factors that increase the risk of QTc prolongation or risk of arrhythmic events (such as heart failure, hypokalemia, congenital long QT syndrome, family history of long QT syndrome or unexplained sudden death under 40 years-of-age)Xx_NEWLINE_xXCushing’s syndromeXx_NEWLINE_xXDiagnosed or suspected congenital long QT syndromeXx_NEWLINE_xXMyelodysplastic syndromeXx_NEWLINE_xXCongenital long QT syndromeXx_NEWLINE_xXDiagnosed or suspected congenital long QT syndrome.Xx_NEWLINE_xXQTc greater than 480 msec or a family or personal history of long or short QT syndrome, Brugada syndrome or know history of QTc prolongation, or Torsade de Pointes (TdP).Xx_NEWLINE_xXResting heart rate <50 bpm or > 90 bpm Long QT syndrome or family history of idiopathic sudden death or congenital long QT syndrome, or any of the following:Xx_NEWLINE_xXPatients who have a history of myelodysplastic syndromeXx_NEWLINE_xXLi-Fraumeni SyndromeXx_NEWLINE_xXPatients with congenital long QT syndrome are excluded from this studyXx_NEWLINE_xXAny factors that increase the risk of QTc prolongation or risk of arrhythmic events such as heart failure, hypokalaemia, congenital or familial long QT syndrome or family history of unexplained sudden death under 40 years of age or any concomitant medications known to prolong QT interval.Xx_NEWLINE_xXDiagnosed or suspected congenital long QT syndromeXx_NEWLINE_xXPatients must have a confirmed diagnosis of non-M3 AML; antecedent myelodysplastic syndrome (MDS) is acceptableXx_NEWLINE_xXHistory of reversible posterior leukoencephalopathy syndrome (RPLS)Xx_NEWLINE_xXHistory of risk factors for TdP, including family history of long QT syndromeXx_NEWLINE_xXHistory of Gilbert’s syndromeXx_NEWLINE_xXKnown history of Gilbert's Syndrome or any current hyperbilirubinemia of any causeXx_NEWLINE_xXCurrent use of drugs known to prolong the QTc interval including class Ia and III antiarrhythmics or history of congenital long QTc syndromeXx_NEWLINE_xXHistory of sarcoidosis syndrome.Xx_NEWLINE_xXAny factors that increase the risk of QTc prolongation or risk of arrhythmic events such as heart failure, hypokalaemia, congenital long QT syndrome, family history of long QT syndrome or unexplained sudden death under 40 years of age or any concomitant medication known to prolong the QT interval.Xx_NEWLINE_xXPatients with myelodysplastic syndrome/acute myeloid leukaemia.Xx_NEWLINE_xXDown SyndromeXx_NEWLINE_xXSubject has active malignant tumors other than AML or myelodysplastic syndrome (MDS).Xx_NEWLINE_xXHas a known history of Gilbert's SyndromeXx_NEWLINE_xXDiagnosis of Myelodysplastic Syndrome.Xx_NEWLINE_xXPresence of risk factors for torsade de pointes, including family history of Long QT Syndrome or uncorrected hypokalemiaXx_NEWLINE_xXClinical evidence of nephrotic syndrome prior to enrollmentXx_NEWLINE_xXHistory of Gilbert’s syndromeXx_NEWLINE_xXHistory of Gilbert's syndromeXx_NEWLINE_xXHistory of Gilbert’s syndromeXx_NEWLINE_xXParticipants with known disorders due to a deficiency in bilirubin glucuronidation (e.g. Gilbert’s syndrome)Xx_NEWLINE_xXHistory of sarcoidosis syndromeXx_NEWLINE_xXDiagnosis of Waldenstrom's macroglobulinemia, POEMS syndrome, plasma cell leukemia, primary amyloidosis, myelodysplastic syndrome, or myeloproliferative syndromeXx_NEWLINE_xXHistory of Gilbert's syndrome.Xx_NEWLINE_xXA history of additional risk factors for torsade de pointes (e.g., heart failure, hypokalemia, family history of long QT syndrome)Xx_NEWLINE_xXPatients with a family history of congenital long QT syndromeXx_NEWLINE_xXParticipants with known disorders due to a deficiency in bilirubin glucuronidation (e.g. Gilbert’s syndrome)Xx_NEWLINE_xXHistory of Gilbert's syndromeXx_NEWLINE_xXPatients with history of Down's syndrome, Fanconi anemia or other known marrow failure conditionXx_NEWLINE_xXLong QT syndrome or a known family history of long QT syndromeXx_NEWLINE_xXNo clinical evidence of heart failure or history of untreated ejection fraction below the lower limit of normal per institutional standards, or significant QT prolongation (> grade 1, 480 msec) no history of congenital long QT syndrome, and no use of drugs known to increase the risk of torsades de point - patients may be eligible for study if the drug can be changed to another agent with less riskXx_NEWLINE_xXIndividuals with Down syndromeXx_NEWLINE_xXBilirubin < to 2.0 x normal (except Gilbert’s Syndrome)Xx_NEWLINE_xXPrior treatment of myelodysplastic syndrome or myeloproliferative neoplasm acceptableXx_NEWLINE_xXCongenital long QT syndrome or a known family history of long QT syndromeXx_NEWLINE_xXAny other significant medical condition not under control, including any acute coronary syndrome within the past 6 monthsXx_NEWLINE_xXHistory of Gilbert’s syndromeXx_NEWLINE_xXMyelodysplastic syndrome with fibrosis (MF 3)Xx_NEWLINE_xXTotal bilirubin =< 2.0 (exceptions may apply to benign non-malignant indirect hyperbilirubinemia such as Gilbert syndrome)Xx_NEWLINE_xXPatients with congenital long QT syndromeXx_NEWLINE_xXCarcinoid SyndromeXx_NEWLINE_xXHas a known history of, or active, neurologic paraneoplastic syndromeXx_NEWLINE_xXNephrotic syndromeXx_NEWLINE_xXBilirubin =< 2 mg/dL (exceptions may apply to benign non-malignant indirect hyperbilirubinemia such as Gilbert syndrome)Xx_NEWLINE_xXNo known malabsorption syndromeXx_NEWLINE_xXDiagnosed congenital long QT syndromeXx_NEWLINE_xXDown syndromeXx_NEWLINE_xXKostmann syndromeXx_NEWLINE_xXShwachman syndromeXx_NEWLINE_xXMyelodysplastic syndrome (MDS): primary or therapy related; orXx_NEWLINE_xXPatients with Down syndrome and deoxyribonucleic acid (DNA) fragility syndromes (such as Fanconi anemia, Bloom syndrome) are excludedXx_NEWLINE_xXPresence of chronic GvHD at Screening (including acute-chronic overlap syndrome).Xx_NEWLINE_xXPreviously untreated for Myelodysplastic Syndrome (MDS)Xx_NEWLINE_xXKnown presence of myelodysplastic syndromeXx_NEWLINE_xXConcomitant genetic syndrome or other known bone marrow failure syndromeXx_NEWLINE_xXDown syndromeXx_NEWLINE_xXCongenital long QT syndromeXx_NEWLINE_xXHistory of congenital long QT syndrome, or a baseline >470 msec QTcF abnormality (average of the triplicate reading).Xx_NEWLINE_xXPersonal or family history of long QT syndromeXx_NEWLINE_xXPatients who are taking medications that prolong QT interval and have a risk of Torsades de Pointes (Appendix F) or who have a history of long QT syndromeXx_NEWLINE_xXKnown presence of myelodysplastic syndromeXx_NEWLINE_xXHistory of Gilbert's syndrome.Xx_NEWLINE_xXPatients with Down syndrome are excluded.Xx_NEWLINE_xXParticipant with acute/chronic GvHD overlap syndromeXx_NEWLINE_xXCongenital long QT syndrome or subjects taking concomitant medications known to prolong the QT interval (e.g., tricyclics, azithromycin, methadone).Xx_NEWLINE_xXSubject is known to have long QT syndrome.Xx_NEWLINE_xXFamily history of long QTc syndromeXx_NEWLINE_xXFamily history of long QTc syndromeXx_NEWLINE_xXMyelodysplastic Syndrome (MDS) at any stage.Xx_NEWLINE_xXPrior treatment with decitabine for myelodysplastic syndrome (MDS) or AMLXx_NEWLINE_xXHistory of Gilbert’s syndromeXx_NEWLINE_xXKnown history of Gilbert’s syndromeXx_NEWLINE_xXKnown presence of myelodysplastic syndromeXx_NEWLINE_xXPatients with a known history of Gilbert’s syndromeXx_NEWLINE_xX4. Known history of Gilbert's Syndrome.Xx_NEWLINE_xXPersonal or family history of established Brugada syndrome; if pre-enrollment electrocardiogram (ECG) demonstrates abnormal findings (ST elevation in precordial leads), cardiology consultation should be obtained to rule out presence of this inherited syndrome; patients with family history of unexplained sudden death before the age 45 years; personal history of unexplained syncope or history of unexplained ventricular tachycardia or fibrillation should have a cardiology evaluation to rule out the diagnosis of Brugada syndromeXx_NEWLINE_xXSézary syndromeXx_NEWLINE_xXPatients with a history of long-QT syndrome or documented family history of long-QT syndrome; patients who must remain on drugs that prolong the QT intervalXx_NEWLINE_xXCongenital long QT syndrome.Xx_NEWLINE_xXActive disease transformation (ie, Richter's Syndrome); subjects with Richter's Syndrome that has resolved > 2 years from signing the ICD are eligible.Xx_NEWLINE_xXPatients with congenital long QT syndromeXx_NEWLINE_xXMyelodysplastic syndrome\r\n* =< 55 years of age and >= 10% blasts, not responsive to hypomethylating agents and/or conventional therapyXx_NEWLINE_xXSubjects with posterior leukoencephalopathy syndromeXx_NEWLINE_xXHistory of neurological conditions that would confound assessment of treatment-emergent neuropathy other than =< grade 1 peripheral neuropathy including multiple sclerosis or other demyelinating disease and/or Eaton-Lambert syndrome (para-neoplastic syndrome); diabetes is allowedXx_NEWLINE_xXDiagnosis of myelodysplastic syndrome (MDS) or a hematologic malignancy.Xx_NEWLINE_xXSubjects who have Gorlin syndromeXx_NEWLINE_xXHistory of hereditary hemorrhagic telangiectasia (HHT, Osler-Weber-Rendu syndrome)Xx_NEWLINE_xXPatients with low- and Int-1-risk myelodysplastic syndromeXx_NEWLINE_xXPatients with a known history or predisposition to cardiac conduction interval abnormalities, including QT Syndrome, or known family history of long QT Syndrome or taking medications that are known to prolong the QT interval.Xx_NEWLINE_xXPersonal or family history of long QT syndromeXx_NEWLINE_xXHistory of sarcoidosis syndromeXx_NEWLINE_xXCongenital long QT syndrome, congestive heart failure, or bradyarrhythmiaXx_NEWLINE_xXPatients with a family history or Li-Fraumeni syndrome will not be eligibleXx_NEWLINE_xXPatients with unexplained syncope, history of or known risk factors for torsade des pointes, including congenital long QT syndrome, or family history of LQTS.Xx_NEWLINE_xXPatient has Down syndromeXx_NEWLINE_xXPatients with known history of Trisomy 21 (Down Syndrome), history of congenital immunodeficiency or inherited marrow failure disorder.Xx_NEWLINE_xXPatients with congenital prolonged QT syndromeXx_NEWLINE_xXCongenital long QT syndromeXx_NEWLINE_xXHistory of Gilbert’s syndromeXx_NEWLINE_xXSubject has active malignant tumors other than AML or Myelodysplastic syndrome (MDS).Xx_NEWLINE_xXCongenital long QT syndromeXx_NEWLINE_xXPatients with myelodysplastic syndromeXx_NEWLINE_xXHistory of congenital long QT syndrome or congenital short QT syndromeXx_NEWLINE_xXPatients with myelodysplastic syndromeXx_NEWLINE_xXCongenital long QT syndromeXx_NEWLINE_xXNephrotic syndromeXx_NEWLINE_xXPatients with a known germline mutation of PTPN11 (Noonan’s Syndrome) are not eligibleXx_NEWLINE_xXCongenital long QT syndrome or family history of unexpected sudden cardiac death.Xx_NEWLINE_xXImmediate family member with a known or suspected Familial Cancer Syndrome (including but not limited to hereditary breast and ovarian cancer syndrome, hereditary non-polyposis colorectal cancer syndrome and familial adenomatous polyposis).Xx_NEWLINE_xXSubject has acute chest syndromeXx_NEWLINE_xXHistory of congenital platelet function defect (e.g., Bernard-Soulier syndrome, Chediak-Higashi syndrome, Glanzmann thrombasthenia, storage pool defect)Xx_NEWLINE_xXHistory of hepatic sinusoid obstructive syndrome (venoocculsive disease) within the prior 3 months.Xx_NEWLINE_xXPatients with myelodysplastic syndrome.Xx_NEWLINE_xXClinically significant ECG changes which obscure the ability to assess the PR, QT, and QRS interval; congenital long QT syndromeXx_NEWLINE_xXDiagnosed or suspected congenital long QT syndromeXx_NEWLINE_xXMalabsorption syndromeXx_NEWLINE_xXHistory of clinically significant cardiac disease, including but not limited to a history (personal or family) of congenital long QT syndromeXx_NEWLINE_xXMyelodysplastic syndrome (MDS)Xx_NEWLINE_xXDiagnosis of smoldering multiple myeloma, Waldenstrom's macroglobulinemia, POEMS syndrome, plasma cell leukemia, primary amyloidosis, myelodysplastic syndrome, or myeloproliferative syndromeXx_NEWLINE_xXHas known gastrointestinal condition or procedure that could interfere with swallowing or the oral absorption of tolerance of IXAZOMIB - Diagnosis of smoldering multiple myeloma, Waldenstrom's macroglobulinemia, POEMS syndrome, plasma cell leukemia, primary amyloidosis, myelodysplastic syndrome, or myeloproliferative syndromeXx_NEWLINE_xXPatients with a history of hereditary hemorrhagic telangiectasia (Osler-Weber-Rendu syndrome)Xx_NEWLINE_xXCongenital long QT syndrome, or 1st degree relative with unexplained sudden death under 40 years of ageXx_NEWLINE_xXCongenital long QT syndrome or family history of unexpected sudden cardiac deathXx_NEWLINE_xXMyelodysplastic syndrome (MDS) with International Prognostic Scoring System (IPSS) intermediate-2 or higher; or therapy-related MDSXx_NEWLINE_xXBilirubin equal or less than 1.5 (unless Gilbert's Syndrome)Xx_NEWLINE_xXhyperviscosity syndrome due to monoclonal gammopathyXx_NEWLINE_xXAcute coronary syndromeXx_NEWLINE_xXPatients with any of the following diagnoses are not eligible:\r\n* Acute promyelocytic leukemia (APL)\r\n* Down syndrome\r\n* Fanconi anemia, Kostmann syndrome, Shwachman syndrome or any other known bone marrow failure syndrome\r\n* Wilson's disease and any other disorder of copper metabolism\r\n* Juvenile myelomonocytic leukemia (JMML)Xx_NEWLINE_xXHistory of Gilbert’s syndromeXx_NEWLINE_xXHistory of congenital long QT syndrome or QTc > 450 msXx_NEWLINE_xXDiagnosed or suspected congenital long QT syndrome;Xx_NEWLINE_xXPatients with Down syndromeXx_NEWLINE_xXKnown malabsorption syndrome, short bowel or chologenic diarrhea not controlled by specific therapeutic meansXx_NEWLINE_xXCongenital long QT syndrome, prolonged QT interval, or family history of sudden unexplained death or long QT syndromeXx_NEWLINE_xXKnown myelodysplastic syndromeXx_NEWLINE_xXKnown myelodysplastic syndrome.Xx_NEWLINE_xXAcute Coronary Syndrome (ACS) (angina or MI) in last 6 months.Xx_NEWLINE_xXDiagnosis of myelodysplastic syndrome (MDS).Xx_NEWLINE_xXKnown Mirizzi syndrome.Xx_NEWLINE_xXHistory of irritable bowel syndrome (IBS)Xx_NEWLINE_xXDelayed gastric emptying syndromeXx_NEWLINE_xXPatients with Sjogren's syndromeXx_NEWLINE_xXDiagnosis of or suspicion of long QT syndrome (including family history of long QT syndrome);Xx_NEWLINE_xXHas difficulty swallowing medications, or known history of malabsorption syndrome;Xx_NEWLINE_xXOngoing or recent hepatorenal syndrome.Xx_NEWLINE_xXHistory of long QT syndrome.Xx_NEWLINE_xXCurrent Myelodysplastic syndrome only subjectsXx_NEWLINE_xXHistory of neuroleptic malignant syndromeXx_NEWLINE_xXPatients with diagnosis of chronic fatigue syndrome (CFS)Xx_NEWLINE_xXPatients with a diagnosis of obesity hypoventilation syndromeXx_NEWLINE_xXSubjects with a history of myelodysplastic syndromeXx_NEWLINE_xXSubjects who have currently active hepatic or biliary disease (with the exception of patients with Gilbert's syndrome)Xx_NEWLINE_xXDiagnosed with hematological malignancy or marrow failure syndrome such as but not limited to: aplastic anemia, myelodysplastic syndrome or leukemiaXx_NEWLINE_xXPatients with acute/chronic GVHD overlap syndromeXx_NEWLINE_xXHistory of irritable bowel syndrome (IBS)Xx_NEWLINE_xXDiagnosed or suspected vasospastic disease such as Raynaud’s syndrome;Xx_NEWLINE_xXMyelodysplatic SyndromeXx_NEWLINE_xXHistory of Guillain-Barre syndromeXx_NEWLINE_xXHistory of Guillain-Barre syndromeXx_NEWLINE_xXPatients with congenital long QT syndromeXx_NEWLINE_xXHave a history of Guillain-Barre syndrome (GBS)Xx_NEWLINE_xXBone marrow failure disorders:\r\n* Paroxysmal nocturnal hemoglobinuria (PNH)\r\n* Hereditary bone marrow failure disorders include Diamond-Blackfan anemia, Shwachman- Diamond syndrome, Kostmann syndrome, and congenital amegakaryocytic thrombocytopenia\r\n* Other non-malignant hematologic or immunologic disorders that require transplantation:\r\n** Quantitative or qualitative congenital platelet disorders (including but not limited to congenital megakaryocytopenia, absent-radii syndrome, Glanzmann’s thrombasthenia)\r\n** Quantitative or qualitative congenital neutrophil disorders (including but not limited to chronic granulomatous disease, congenital neutropenia)\r\n** Congenital primary immunodeficiencies (including but not limited to severe combined immunodeficiency syndrome, Wiskott-Aldrich syndrome, CD40 ligand deficiency, T-cell deficiencies)\r\n** Hemoglobinopathies (including sickle cell disease and thalassemia)Xx_NEWLINE_xXFamilial short QT syndromeXx_NEWLINE_xXPatients with known or suspected Gilbert’s syndrome at the time of study enrollmentXx_NEWLINE_xXIntermediate (Int)-2 or high risk myelodysplastic syndrome (MDS)Xx_NEWLINE_xXGrade 3 or higher recent (within the past 6 months) or ongoing cardiac dysrhythmias, family history of long QT syndrome, or serum potassium < 3.0 mEq/L that is persistent and refractory to correctionXx_NEWLINE_xXDown syndromeXx_NEWLINE_xXCongenital long QT syndrome, or 1st degree relative with unexplained sudden death under 40 years of age;Xx_NEWLINE_xXShort gut syndromeXx_NEWLINE_xXAny malabsorption disease/syndromeXx_NEWLINE_xXMyelodysplastic syndrome (MDS): transfusion-dependent, or intermediate or higher IPSS-R risk groupXx_NEWLINE_xXHistory of atrophic gastritis, pernicious anemia, or Zollinger-Ellison syndromeXx_NEWLINE_xXSubjects who have Gorlins syndromeXx_NEWLINE_xXSubjects with hypothyroidism (eg, following Hashimoto syndrome) stable on hormone replacement for ? 3 months; orXx_NEWLINE_xXSubjects with treatment-related myelodysplastic syndrome.Xx_NEWLINE_xXSubject has a history (or family history) of long QT syndrome.Xx_NEWLINE_xXA defined myelodysplastic syndrome(s) (MDS)Xx_NEWLINE_xXCongenital long QT syndrome or 1st degree relative with unexplained sudden death under 40 years of ageXx_NEWLINE_xXDiagnosis of Down's SyndromeXx_NEWLINE_xXHistory of Stevens-Johnson syndromeXx_NEWLINE_xXHistory of Stevens-Johnson syndromeXx_NEWLINE_xXPatients with respiratory distress syndromeXx_NEWLINE_xXPatients who have experienced an acute coronary syndrome or angina in the past 6 monthsXx_NEWLINE_xXPATIENT: Patients with respiratory distress syndromeXx_NEWLINE_xXPatients with unstable cardiopulmonary conditions or respiratory distress syndromeXx_NEWLINE_xXHas any factors that increase the risk of corrected QT (QTc) interval prolongation or risk of arrhythmic events, such as congenital long QT syndrome, family history of long QT syndrome, or unexplained sudden death under 40 years of age in first-degree relatives.Xx_NEWLINE_xXHistory of Steven’s Johnson’s syndrome, toxic epidermal necrolysis syndrome (TENs) or motor neuropathyXx_NEWLINE_xXPre-existing renal disease including glomerulonephritis, nephritic syndrome, Fanconi syndrome or renal tubular acidosisXx_NEWLINE_xXConcomitant medications known to prolong QT interval, or with factors that increase the risk of QTc prolongation or risk of arrhythmic events (such as heart failure, hypokalemia, congenital long QT syndrome, family history of long QT syndrome or unexplained sudden death under 40 years-of-age)Xx_NEWLINE_xXSubjects with Gilbert's syndrome or resolving autoimmune hemolytic anemia may have a bilirubin up to 3.0 x ULN and are still eligibleXx_NEWLINE_xXSubject with Long QT Syndrome.Xx_NEWLINE_xXPatients with respiratory distress syndromeXx_NEWLINE_xXPatients with respiratory distress syndromeXx_NEWLINE_xXHistory of Brugada syndrome, risk factors for TdP, or family history of long QT syndrome.Xx_NEWLINE_xXCongenital long QT syndrome or a known family history of long QT syndromeXx_NEWLINE_xXMyelodysplastic SyndromeXx_NEWLINE_xXHistory or evidence of giant congenital melanocytic nevi, dysplastic nevis syndrome or xeroderma pigmentosum.Xx_NEWLINE_xXBilirubin >1.5 x ULN, unless prior diagnosis and documentation of leukemic organ involvement, ongoing hemolysis, or Gilbert's syndromeXx_NEWLINE_xXHistory of Stevens-Johnson syndrome or toxic epidermal necrolysis syndrome.Xx_NEWLINE_xXHistory of Guillain-Barre syndrome or Stevens-Johnson syndromeXx_NEWLINE_xX